In the present study, even though most MS-TBI patients were on immune-modulating therapy, the total lymphocyte count was in the normal number range and did not impact TB1 or TB2 response, and all subjects responded to mitogens. This evidence concerns the gene REEP5 and myeloid sarcoma.